Shanghai Junshi Biosciences Co., Ltd. (Junshi Bio) confirmed that Chairman and co-controlling shareholder Xiong Jun has completed his previously announced share-purchase plan, acquiring 3.26 million A and H shares between 10 November 2025 and 31 March 2026. The purchases, executed via Shanghai and Hong Kong bourses through centralised bidding and block trades, totalled RMB100.64 million—exceeding the minimum RMB100 million commitment outlined on 12 April 2025.\n\nFollowing the transactions, the combined holding of Xiong Jun, fellow controlling shareholder Xiong Fengxiang, and their concert-party investors (including Shanghai Baoying Asset Management, Meng Xiaojun, Gao Shufang, Zhuhai Huapu Investment Management, Zhou Yuqing, Liu Xiaoling and Wang Lifang) increased from 17.92% to 18.24% of Junshi Bio’s 1.03 billion outstanding shares. The 0.32-percentage-point uplift crossed the statutory 1% incremental disclosure threshold but does not trigger a mandatory general offer.\n\nXiong Jun’s direct stake rose from 8.56% to 8.87% after purchasing 2.36 million A shares and 0.89 million H shares. All acquisitions were funded with personal resources. No changes occurred in Junshi Bio’s controlling shareholder structure, and the company stated that its public float remains compliant with listing requirements.\n\nJunshi Bio reiterated that the share-purchase plan has now been fully executed, with no further increases mandated under the disclosed programme.